
{
  "documentMetadata": {
    "title": "Pneumonia caused by Stenotrophomonas maltophilia",
    "sourceFile": "Pneumonia, Stenotrophomonas maltophilia.pdf",
    "lastUpdated": "2025-05-06"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Specific therapy for hospital acquired pneumonia (HAP) caused by Stenotrophomonas maltophilia.",
        "Immunocompromised and/or debilitated pateints are predisposed.",
        "Positive blood or sputum culture.",
        "For further discussion of susceptibility and resistance, see Stenotrophomonas maltophilia."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Stenotrophomonas maltophilia"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "strengthOfRecommendation": "Recommended",
        "components": [
          {
            "drug": "TMP-SMX",
            "dose": "10-15 mg/kg/day",
            "route": "IV/po",
            "frequency": "divided q8h or q12h",
            "notes": "dosed based on TMP component"
          },
          {
            "drug": "Minocycline",
            "dose": "200 mg",
            "route": "IV/po",
            "frequency": "q12h",
            "notes": "see Comments",
            "connector": "+"
          }
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "strengthOfRecommendation": "Alternative",
        "notes": "Combination therapy with two of the following agents",
        "components": [
          {
            "drug": "TMP-SMX",
            "dose": "10-15 mg/kg/day",
            "route": "IV/po",
            "frequency": "divided q8h or q12h"
          },
          {
            "drug": "Levofloxacin",
            "dose": "750 mg",
            "route": "IV/po",
            "frequency": "q24h"
          },
          {
            "drug": "Minocycline",
            "dose": "200 mg",
            "route": "IV/po",
            "frequency": "q12h"
          },
          {
            "drug": "Tigecycline",
            "dose": "200 mg",
            "route": "IV x1, then 100 mg IV q12h"
          },
          {
            "drug": "Cefiderocol",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q8h",
            "notes": "infused over 3 hours, Clin Infect Dis 2022; 74:2089"
          }
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Depending on severity of illness, with source control, and in vitro susceptibility, and clinical response can de-escalate to oral monotherapy with TMP-SMX (preferred) or Minocycline."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Another salvage therapy based mainly on in vitro studies (Antimicrob Agents Chemother 2017; 61:e00777-17) and case reports: Ceftazidime-avibactam 2.5 gm IV over 3h q8h + Aztreonam 2 gm IV over 2h q8h",
        "Based on observational evidence levofloxacin is a reasonable alternative to TMP-SMX for the treatment of bloodstream and lower respiratory tract infections caused by S. maltophilia (Open Forum Infect Dis. 2022; 9:ofab644).",
        "There is no standard of care regimen. IDSA guidance (Clin Infect Dis. 2024 Aug 7:ciae403) is to use combination therapy in a effort to prevent emergence of resistance on therapy, which is common, with the agents listed above.",
        "Omadacycline and Eravacycline active in vitro but no clinical data",
        "For status of in vitro susceptibility against 1,839 isolates: Antimicrob Agents Chemother 2020;64: e01433-20",
        "TMP-SMX and Minocycline were most active of the drugs tested",
        "Cefiderocol and Eravacycline were not tested"
      ]
    }
  ]
}
